Pyramid Biosciences appoints Dr. Brian Lestini as CEO alongside Dr. Kollol Pal remaining as CSO

– USA, MA –  Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the appointment of Dr. Brian Lestini (MD, Ph.D.) as CEO, succeeding the co-founder and current CEO Dr. Kollol Pal who will continue to serve as CSO, where he will lead all pre-clinical development activities.

About Dr. Brian Lestini

Dr. Lestini joined Pyramid Biosciences in March 2021 as the CMO, overseeing the advancement and expansion of the clinical pipeline of novel targeted medicines. Pyramid Biosciences’ lead program, PBI-200, currently in Phase 1 clinical trials, is an orally-active, CNS penetrant TRK inhibitor targeting a variety of genetically defined cancers, including primary and metastatic brain cancers.

“I would like to thank Dr. Pal for his pioneering leadership,” said Dr. Lestini. “Pyramid Biosciences has grown immensely over the past seven years under Dr. Pal’s stewardship, and I’m excited to help the company take the next step in our growth and achieve Dr. Pal’s vision of bringing Pyramid’s precision oncology therapies to underserved patients throughout the world.”

An experienced leader in early- and late-stage oncology clinical development, Dr. Lestini oversaw development and commercialization strategies for checkpoint inhibitor therapies including OPDIVO (nivolumab) and relatlimab (anti-LAG3 checkpoint inhibitor), a novel immune-oncology agent applied to a wide range of cancers, at Bristol-Myers Squibb (NYSE: BMY). Dr. Lestini also served as the Head of Global Medical Affairs at Bristol-Myers Squibb for three hematology products: OPDIVO (nivolumab), SPRYCEL (dasatinib), and EMPLICITI (elotuzumab). Before joining Bristol-Myers Squibb, Dr. Lestini led early-stage clinical development programs at Hoffmann-La Roche (OTCMKTS: RHHBY).

Dr. Lestini is a board-certified pediatric hematologist-oncologist. He received his medical degree (MD) and Doctor of Philosophy (Ph.D.) degree from Case Western Reserve University and completed his fellowship training at the Children’s Hospital of Philadelphia.

About Pyramid Biosciences Inc.

Founded in 2015, Pyramid Biosciences is a clinical-stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Pyramid is currently in clinical development of two highly selective tropomyosin receptor kinase inhibitors.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.